|
|
|
|
| LEADER |
03545nam a2200757Ia 4500 |
| 001 |
10.1016-j.addbeh.2018.02.024 |
| 008 |
220706s2018 CNT 000 0 und d |
| 020 |
|
|
|a 03064603 (ISSN)
|
| 245 |
1 |
0 |
|a Criminal justice continuum for opioid users at risk of overdose
|
| 260 |
|
0 |
|b Elsevier Ltd
|c 2018
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1016/j.addbeh.2018.02.024
|
| 520 |
3 |
|
|a The United States (US) is in the midst of an epidemic of opioid use; however, overdose mortality disproportionately affects certain subgroups. For example, more than half of state prisoners and approximately two-thirds of county jail detainees report issues with substance use. Overdose is one of the leading causes of mortality among individuals released from correctional settings. Even though the criminal justice (CJ) system interacts with a disproportionately high number of individuals at risk of opioid use and overdose, few CJ agencies screen for opioid use disorder (OUD). Even less provide access to medication assisted treatment (e.g. methadone, buprenorphine, and depot naltrexone), which is one of the most effective tools to combat addiction and lower overdose risk. However, there is an opportunity to implement programs across the CJ continuum in collaboration with law enforcement, courts, correctional facilities, community service providers, and probation and parole. In the current paper, we introduce the concept of a “CJ Continuum of Care for Opioid Users at Risk of Overdose” grounded by the Sequential Intercept Model. We present each step on the CJ Continuum and include a general overview and highlight opportunities for: 1) screening for OUD and overdose risk, 2) treatment and/or diversion, and 3) overdose prevention and naloxone provision. © 2018 Elsevier Ltd
|
| 650 |
0 |
4 |
|a Analgesics, Opioid
|
| 650 |
0 |
4 |
|a Article
|
| 650 |
0 |
4 |
|a buprenorphine
|
| 650 |
0 |
4 |
|a criminal justice
|
| 650 |
0 |
4 |
|a Criminal justice
|
| 650 |
0 |
4 |
|a criminal law
|
| 650 |
0 |
4 |
|a Criminal Law
|
| 650 |
0 |
4 |
|a delayed release formulation
|
| 650 |
0 |
4 |
|a Delayed-Action Preparations
|
| 650 |
0 |
4 |
|a drug overdose
|
| 650 |
0 |
4 |
|a Drug Overdose
|
| 650 |
0 |
4 |
|a health care access
|
| 650 |
0 |
4 |
|a health care cost
|
| 650 |
0 |
4 |
|a health program
|
| 650 |
0 |
4 |
|a high risk patient
|
| 650 |
0 |
4 |
|a human
|
| 650 |
0 |
4 |
|a Humans
|
| 650 |
0 |
4 |
|a intoxication
|
| 650 |
0 |
4 |
|a Judicial Role
|
| 650 |
0 |
4 |
|a jurisprudence
|
| 650 |
0 |
4 |
|a law enforcement
|
| 650 |
0 |
4 |
|a Law Enforcement
|
| 650 |
0 |
4 |
|a mass screening
|
| 650 |
0 |
4 |
|a Mass Screening
|
| 650 |
0 |
4 |
|a mental health care
|
| 650 |
0 |
4 |
|a methadone
|
| 650 |
0 |
4 |
|a naltrexone
|
| 650 |
0 |
4 |
|a Naltrexone
|
| 650 |
0 |
4 |
|a narcotic analgesic agent
|
| 650 |
0 |
4 |
|a narcotic antagonist
|
| 650 |
0 |
4 |
|a Narcotic Antagonists
|
| 650 |
0 |
4 |
|a opiate
|
| 650 |
0 |
4 |
|a opiate addiction
|
| 650 |
0 |
4 |
|a opiate substitution treatment
|
| 650 |
0 |
4 |
|a Opiate Substitution Treatment
|
| 650 |
0 |
4 |
|a Opioid overdose
|
| 650 |
0 |
4 |
|a Opioid-Related Disorders
|
| 650 |
0 |
4 |
|a patient education
|
| 650 |
0 |
4 |
|a prison
|
| 650 |
0 |
4 |
|a Prisons
|
| 650 |
0 |
4 |
|a public health
|
| 650 |
0 |
4 |
|a public-private partnership
|
| 650 |
0 |
4 |
|a risk assessment
|
| 650 |
0 |
4 |
|a Risk Assessment
|
| 650 |
0 |
4 |
|a screening test
|
| 650 |
0 |
4 |
|a United States
|
| 700 |
1 |
|
|a Brinkley-Rubinstein, L.
|e author
|
| 700 |
1 |
|
|a Cloud, D.H.
|e author
|
| 700 |
1 |
|
|a Heise, A.
|e author
|
| 700 |
1 |
|
|a Martino, S.
|e author
|
| 700 |
1 |
|
|a McCauley, E.
|e author
|
| 700 |
1 |
|
|a Seal, D.
|e author
|
| 700 |
1 |
|
|a Zaller, N.
|e author
|
| 773 |
|
|
|t Addictive Behaviors
|
